Humacyte Announces the Appointments of Three Surgical and Cardiovascular Opinion Leaders to ...

DURHAM, N.C., Dec. 31, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced the appointment

Related Keywords

Laura Niklason ,Kols Alanp Kypson ,Todde Rasmussen ,Luigi Pascarella ,Brody School Of Medicine ,University Of North Carolina Rex Hospital ,Drug Administration ,Vascular Biology Research Fellowship ,Carolina Heart Institute ,Us Air ,Nasdaq ,Humacyte Inc ,Division Of Cardiothoracic Surgery ,University Of North Carolina School Medicine ,Duke University ,Surgical Key Opinion Leaders ,Human Acellular ,Mayo Clinic ,Chief Executive Officer ,North Carolina Rex Hospital ,Brody School ,Cardiothoracic Surgery ,East Carolina Heart ,Associate Professor ,North Carolina School ,Chapel Hill ,California San Diego ,Air Force ,Middle East ,Patient Care ,Vascular Disease ,Humacyte ,Medicine Advanced Therapy ,Investor Contact ,Media Contact ,Money ,Ational ,